Article
Radiology, Nuclear Medicine & Medical Imaging
David A. Pattison, Maciej Debowski, Brook Gulhane, Evyn G. Arnfield, Anita M. Pelecanos, Peter L. Garcia, Melissa J. Latter, Charles Y. Lin, Matthew J. Roberts, Stuart C. Ramsay, Paul A. Thomas
Summary: This study aimed to compare the concordance of [F-18]PSMA-1007 and [(68)Ga]Ga-PSMA-11 in TNM diagnosis and tracer uptake. The results showed differences in tracer uptake in most physiological sites, but high consistency in overall AJCC prognostic stage.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Sebastian Hoberuck, Steffen Lock, Angelika Borkowetz, Ulrich Sommer, Robert Winzer, Klaus Zophel, Dieter Fedders, Enrico Michler, Jorg Kotzerke, Klaus Kopka, Tobias Holscher, Anja Braune
Summary: In prostate cancer patients, the two radiotracers showed interchangeable performance in miTNM staging, with more differences found in presumable unspecific lesions, particularly in the detection of nonspecific bone findings by [F-18]-F-PSMA-1007.
Article
Medicine, General & Internal
Katelijne C. C. de Bie, Hans Veerman, Yves J. L. Bodar, Dennie Meijer, Pim J. van Leeuwen, Henk G. van der Poel, Maarten L. Donswijk, Andre N. Vis, Daniela E. Oprea-Lager
Summary: This study investigated the association between the expression of Ga-68- or F-18-radiolabeled prostate-specific membrane antigen (PSMA) tracer and biochemical recurrence (BCR) in primary prostate cancer (PCa) patients prior to robot-assisted radical prostatectomy (RARP). The study found that SUVmax was an independent predictor for BCR in [Ga-68]Ga-PSMA-11 and [F-18]DCFPyL-120 PET/CT scans.
Article
Medicine, General & Internal
Manuela A. Hoffmann, Jonas Mueller-Huebenthal, Florian Rosar, Nicolas Fischer, Finn Edler von Eyben, Hans-Georg Buchholz, Helmut J. Wieler, Mathias Schreckenberger
Summary: This study compared the performance of [F-18]PSMA-1007 and [Ga-68]Ga-PSMA-11 positron emission tomography/computed tomography in the initial staging of prostate cancer patients. The results showed that both methods were able to detect PSMA-avid lesions with high concordance to histopathologically proven cancer. There was no superior advantage of either method in diagnosing prostate cancer.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Yining Wang, Zijun Chen, Yinjie Zhu, Haitao Zhao, Lianghua Li, Gang Huang, Wei Xue, Ruohua Chen, Jianjun Liu
Summary: The purpose of this study was to assess whether total-body [(68) Ga]Ga-PSMA-11 PET/CT could improve the detection rate compared with conventional [(68) Ga]Ga-PSMA-11 PET/CT in patients with biochemical recurrent prostate cancer. The results showed that total-body [(68) Ga]Ga-PSMA-11 PET/CT had better objective evaluation in terms of background noise, lesion prominence, liver SD, SNR, and lesion SUVmax compared with conventional [(68) Ga]Ga-PSMA-11 PET/CT. Overall, total-body [(68) Ga]Ga-PSMA-11 PET/CT had a significantly higher detection rate for biochemical recurrent prostate cancer compared to conventional [(68) Ga]Ga-PSMA-11 PET/CT. Rating: 9/10.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Jan Heilinger, Jasmin Weindler, Katrin Sabine Roth, Philipp Krapf, Klaus Schomaecker, Markus Dietlein, Alexander Drzezga, Carsten Kobe
Summary: The study found that there was no difference in tumour-to-liver and tumour-to-mediastinum ratios between [F-18]F-DCFPyL-PET and [Ga-68]Ga-PSMA-11-PET, indicating that [F-18]F-DCFPyL can be considered equally suitable for defining PSMA-positivity based on the liver background. Additionally, [F-18]F-DCFPyL showed a potential advantage in lesion detectability compared to [Ga-68]Ga-PSMA-11.
Article
Oncology
Wenxiao Yu, Ming Zhao, Yingjun Deng, Shengjing Liu, Guanchao Du, Bin Yan, Ziwei Zhao, Ning Sun, Jun Guo
Summary: This study compared the diagnostic value of (18) F-PSMA-1007 PET/CT, (18) F-FDG PET/CT, and Ga-68-PSMA PET/CT in prostate cancer. The results showed that both (18) F-PSMA-1007 PET/CT and Ga-68 PSMA PET/CT demonstrated higher diagnostic efficacy compared to (18) F-FDG PET/CT.
Article
Multidisciplinary Sciences
Sarah Piron, Jeroen Verhoeven, Jan Courtyn, Ken Kersemans, Benedicte Descamps, Leen Pieters, Anne Vral, Christian Vanhove, Filip De Vos
Summary: The study compared the performance of [F-18]AlF-PSMA-11 and [F-18]PSMA-1007 in mice, demonstrating that [F-18]PSMA-1007 had higher uptake in high PSMA expressing tumors. However, [F-18]AlF-PSMA-11 showed better performance in low PSMA expressing tumors and [F-18]PSMA-1007 exhibited higher uptake in healthy organs.
SCIENTIFIC REPORTS
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Priya Sharma, Ankit Watts, Harmandeep Singh
Summary: This study compared the biodistribution and internal dosimetry of F-18-PSMA-1007 and Ga-68-PSMA-11-HBED-CC and found that F-18-PSMA-1007 had higher whole-body effective dose and lower urinary bladder clearance, which could allow better interpretation of the prostatic bed without significant radioactive urine interference.
CLINICAL NUCLEAR MEDICINE
(2022)
Article
Oncology
Manuela A. Hoffmann, Finn Edler von Eyben, Nicolas Fischer, Florian Rosar, Jonas Muller-Hubenthal, Hans-Georg Buchholz, Helmut J. Wieler, Mathias Schreckenberger
Summary: PSMA hybrid imaging can improve the diagnosis of recurrent prostate cancer. This study compared the diagnostic performance of [F-18]PSMA-1007 PET/CT and [Ga-68]Ga-PSMA-11 PET/CT by identifying PSA threshold levels. The results showed similar findings for both methods.
Review
Oncology
Ruizhe Huang, Yizhen Li, Haowen Wu, Boyi Liu, Xuanjun Zhang, Zhongxi Zhang
Summary: The aim of this study was to compare the diagnostic efficacy of Ga-68-PSMA-11 PET/CT and Ga-68-PSMA-11 PET/MRI in patients with biochemically recurrent prostate cancer. A meta-analysis and systematic review were conducted, analyzing 37 studies involving 8409 patients. The results showed that Ga-68-PSMA-11 PET/CT and Ga-68-PSMA-11 PET/MRI had similar detection rates for biochemically recurrent prostate cancer. However, larger prospective studies are needed to confirm these findings.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Emil Novruzov, Dominik Schmitt, Katalin Mattes-Gyoergy, Markus Beu, Yuriko Mori, Mardjan Dabir, Jan Philipp Radtke, Guenter Niegisch, Peter Albers, Lars Schimmoeller, Gerald Antoch, Christina Antke, Frederik L. Giesel, Eduards Mamlins
Summary: Through a study on 19 male patients with prostate cancer, it was found that there is a higher detection rate of ganglia in imaging with [18F]PSMA-1007 compared to [68Ga]Ga-PSMA-11. The study also suggests that the better detectability is not due to higher uptake but rather more favorable physical properties of [F-18]PSMA-1007.
Editorial Material
Radiology, Nuclear Medicine & Medical Imaging
Jiayu Cai, Weizhi Xu, Tinghua Meng, YiZhen Pang, Haojun Chen
Summary: Mixed neuroendocrine carcinoma-acinar carcinoma is a rare type of neuroendocrine prostate cancer and has rarely been reported in de novo cases. In this case, we present the PET/CT findings of Ga-68-PSMA, Ga-68-FAPI, and F-18-FDG in the de novo form of mixed large-cell neuroendocrine carcinoma-acinar adenocarcinoma of the prostate. Different levels of radiotracer uptake were observed in metastatic sites on Ga-68-PSMA, Ga-68-FAPI, and F-18-FDG PET/CT. This case demonstrates the potential use of a multitracer PET/CT strategy for noninvasive detection of intermetastatic heterogeneity in metastatic neuroendocrine prostate cancer.
CLINICAL NUCLEAR MEDICINE
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Yuheng Liu, Lianghua Li, Yanyu Qin, Zijun Chen, Haitao Zhao, Xinlu Wang, Ruohua Chen
Summary: The objective of this study was to compare the diagnostic performance and image quality of total-body PET/CT imaging using half-dose of [(68) Ga]Ga-PSMA radiotracer to conventional PET/CT imaging using full dose of [(68) Ga]Ga-PSMA. The results showed that total-body PET/CT with half-dose of [(68) Ga]Ga-PSMA yielded comparable image quality and diagnostic performance to conventional PET/CT, while reducing radiation exposure for the subjects.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2023)
Article
Biochemistry & Molecular Biology
Costantina Maisto, Michela Aurilio, Anna Morisco, Roberta de Marino, Monica Josefa Buonanno Recchimuzzo, Luciano Carideo, Laura D'Ambrosio, Francesca Di Gennaro, Aureliana Esposito, Paolo Gaballo, Valentina Pirozzi Palmese, Valentina Porfidia, Marco Raddi, Alfredo Rossi, Elisabetta Squame, Secondo Lastoria
Summary: The aim of this study was to compare [Ga-68]Ga-PSMA-11 and [F-18]PSMA-1007 PET/CT as imaging agents in prostate cancer patients. The results showed that both radioligands had similar detection rates for prostate cancer lesions, but had significantly different distribution in normal organs. Additionally, the analysis of cost-effectiveness suggested that [F-18]PSMA-1007 had major advantages over [Ga-68]Ga-PSMA-11.
Article
Critical Care Medicine
Daniel C. Schroeder, Erik Popp, Cathrin Rohleder, Stefanie Vus, David de la Puente Bethencourt, Simon R. Finke, Boris D. Zlatopolskiy, Johannes Zischler, Alexander Drzezga, Holger Herff, Thorsten Annecke, Tim Hucho, Bernd Neumaier, Bernd W. Boettiger, Heike Endepols
Summary: Neuroinflammation mediated by TSPO-expressing cells persists long-term after sudden cardiac arrest, potentially impacting cognitive functions. PET imaging and immunohistochemistry confirmed significant accumulation of TSPO in brain regions such as the dorsal hippocampus and striatum.
Article
Radiology, Nuclear Medicine & Medical Imaging
Jochen Hammes, Gerard N. Bischof, Karl P. Bohn, Oezguer Onur, Anja Schneider, Klaus Fliessbach, Merle C. Hoenig, Frank Jessen, Bernd Neumaier, Alexander Drzezga, Thilo van Eimeren
Summary: The study revealed that F-18-flortaucipir PET can effectively differentiate between amyloid-positive and-negative neurodegenerative diseases, with high accuracy achieved through pattern expression strengths in SSM/PCA components.
JOURNAL OF NUCLEAR MEDICINE
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Felix Dietlein, Peter Mueller, Carsten Kobe, Heike Endepols, Melanie Hohberg, Boris D. Zlatopolskiy, Philipp Krapf, Axel Heidenreich, Bernd Neumaier, Alexander Drzezga, Markus Dietlein
Summary: PSMA imaging, specifically with [F-18]-JK-PSMA-7 PET, shows high detection rates in patients with PSA levels >= 0.3 ng/ml under ADT. The lower PSA threshold of 0.3 ng/ml for high detection rates is consistent across different PSMA ligands, making PSMA imaging suitable for clinical follow-up of patients with increasing PSA levels under ADT.
MOLECULAR IMAGING AND BIOLOGY
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Gerard N. Bischof, Peter Bartenstein, Henryk Barthel, Bart van Berckel, Vincent Dore, Thilo van Eimeren, Norman Foster, Jochen Hammes, Adriaan A. Lammertsma, Satoshi Minoshima, Chris Rowe, Osama Sabri, John Seibyl, Koen Van Laere, Rik Vandenberghe, Victor Villemagne, Igor Yakushev, Alexander Drzezga
Summary: This study found that there were no significant differences in using different approved visual rating protocols across the expert group for all F-18-labeled amyloid tracers, while significant differences were observed in the nonexpert group.
JOURNAL OF NUCLEAR MEDICINE
(2021)
Article
Oncology
Philipp Linde, Christian Baues, Simone Wegen, Maike Trommer, Alexander Quaas, Johannes Rosenbrock, Eren Celik, Simone Marnitz, Christiane J. Bruns, Thomas Fischer, Klaus Schomaecker, Hans-Juergen Wester, Alexander Drzezga, Lutz van Heek, Carsten Kobe
Summary: The expression of CXCR4 in solid tumors plays a key role in tumor growth and metastasis. This study compared the use of FDG-PET/CT and Pentixafor-PET/CT in esophageal cancer patients, showing differences in lesion identification and suggesting that Pentixafor PET/CT could serve as a complementary tool in radiation treatment.
Article
Biochemistry & Molecular Biology
Chris Hoffmann, Sibel Evcueman, Felix Neumaier, Boris D. Zlatopolskiy, Swen Humpert, Dirk Bier, Marcus Holschbach, Annette Schulze, Heike Endepols, Bernd Neumaier
Summary: Selective inhibition of GlyT1 with ALX5407 has shown potential in alleviating NMDAR hypofunction in patients with schizophrenia and cognitive decline. However, clinical application of ALX5407 is limited by adverse effects, suggesting the need for a radiolabeled drug as a PET tracer. In this study, [F-18]ALX5406 was found to be a promising PET probe for preclinical in vivo imaging of GlyT1 in the brain, showing regional accumulation consistent with GlyT1 specific binding.
ACS CHEMICAL NEUROSCIENCE
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Sergio Munoz Vazquez, Heike Endepols, Thomas Fischer, Samir-Ghali Tawadros, Melanie Hohberg, Beate Zimmermanns, Felix Dietlein, Bernd Neumaier, Alexander Drzezga, Markus Dietlein, Klaus Schomaecker
Summary: A Zr-89-labeled inhibitor of prostate-specific membrane antigen (PSMA) was presented as a complement to established F-18 or Ga-68 ligands. The study showed promising results in terms of tumor imaging and detection of areas with lower PSMA expression, warranting further clinical evaluation.
MOLECULAR IMAGING AND BIOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Viktoriya V. Orlovskaya, Austin S. Craig, Olga S. Fedorova, Olga F. Kuznetsova, Bernd Neumaier, Raisa N. Krasikova, Boris D. Zlatopolskiy
Summary: A practical method for the preparation of 6-L-[F-18]FMT using radiofluorination has been developed, providing a high activity yield of 20%. This method can be easily applied in clinical settings and allows for quick switching between C-11 and F-18 labeling.
Article
Psychology, Clinical
Franziska Maier, Andrea Greuel, Marius Hoock, Rajbir Kaur, Masoud Tahmasian, Frank Schwartz, Ilona Csoti, Frank Jessen, Alexander Drzezga, Thilo van Eimeren, Lars Timmermann, Carsten Eggers
Summary: This study investigated impaired self-awareness of cognitive deficits in Parkinson's disease (PD) and its associations with clinical-behavioral and neuroimaging markers. The results showed that PD patients with mild cognitive impairment (PD-MCI) had significantly higher impaired self-awareness than healthy controls and PD patients without MCI. Neuroimaging analysis revealed that glucose metabolism in the cingulate cortex was negatively correlated with impaired self-awareness. In PD-MCI patients, impaired self-awareness was associated with decreased metabolism in the right temporal lobe, insula, and midcingulate cortex. These findings suggest that impaired self-awareness of cognitive deficits in PD may be related to disruptions in the cognitive network and metabolic changes in specific brain regions.
PSYCHOLOGICAL MEDICINE
(2023)
Article
Neurosciences
Heike Endepols, Boris D. Zlatopolskiy, Johannes Zischler, Nazanin Alavinejad, Nadine Apetz, Stefanie Vus, Alexander Drzezga, Bernd Neumaier
Summary: The study demonstrated the visualization of inflammation related to the kynurenine pathway and changes in serotonin synthesis using the novel PET tracer. The 7-[F-18]FTrp PET tracer has great potential in localizing pathway alterations in the brain.
Article
Neurosciences
Heike Endepols, Marta Anglada-Huguet, Eckhard Mandelkow, Yannick Schmidt, Philipp Krapf, Boris D. Zlatopolskiy, Bernd Neumaier, Eva-Maria Mandelkow, Alexander Drzezga
Summary: Cerebral glucose hypometabolism, a key feature of Alzheimer's disease (AD), is related to neurodegeneration and neuronal dysfunction. However, the underlying pathological processes and reproducibility in animal models are not well understood. This study used PET tracers to investigate the relationship between glucose hypometabolism and various molecular targets of AD pathophysiology. The findings revealed that hypometabolism was associated with Tau pathology, neuroinflammation, and synaptic loss in certain brain regions, while hypometabolism in the thalamus occurred independently of tau-related pathology. This study highlights the complexity of AD pathomechanisms and provides insights for future research and investigations in human patients.
MOLECULAR NEUROBIOLOGY
(2022)
Article
Chemistry, Medicinal
Nils Walter, Jan Bertram, Birte Drewes, Victor Bahutski, Marco Timmer, Markus B. Schuetz, Felicia Kraemer, Felix Neumaier, Heike Endepols, Bernd Neumaier, Boris D. Zlatopolskiy
Summary: A protocol for radiolabeling of aryl fluorosulfates using ultrafast isotopic exchange has been developed and optimized. This method allows for efficient labeling of low nanomolar amounts of aryl fluorosulfates without the need for azeotropic drying, base addition, and HPLC purification. The labeled compounds demonstrated sufficient stability in vivo and showed promise as tracers for visualizing specific molecular expressions.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
(2022)
Article
Chemistry, Multidisciplinary
Chris Hoffmann, Niklas Kolks, Daniel Smets, Alexander Haseloer, Benedikt Groener, Elizaveta A. Urusova, Heike Endepols, Felix Neumaier, Uwe Ruschewitz, Axel Klein, Bernd Neumaier, Boris D. Zlatopolskiy
Summary: In this study, a series of complexes were systematically evaluated and several generally applicable mediators were identified for highly efficient radiofluorination. The utilization of these mediators significantly improved the labeling yields, even with lower precursor amounts. The practicality of the novel mediators was demonstrated by the efficient production of five PET tracers and transfer of the method to an automated radiosynthesis module.
CHEMISTRY-A EUROPEAN JOURNAL
(2023)
Review
Biochemistry & Molecular Biology
Felix Neumaier, Boris D. D. Zlatopolskiy, Bernd B. Neumaier
Summary: In this review titled "Prospects and challenges for the application of mutated IDH PET probes in gliomas", the authors summarize the rationale behind the development of mutated IDH PET probes, describe their potential applications beyond IDH status assessment, and highlight potential challenges in tracer development. The authors also compile the major chemical classes of mutated IDH-selective inhibitors that have been described to date, briefly consider possible strategies for radiolabeling of the most promising candidates, and assess the suitability of radiolabeled analogs of mutated IDH inhibitors for PET imaging in gliomas.